{"id":"W4409077337","doi":"10.1136/bmjgast-2024-001615","title":"Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial","year":2025,"lang":"en","type":"article","venue":"BMJ Open Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University; Ottawa Hospital; University of British Columbia; University of Ottawa; Montreal General Hospital; McMaster University; Population Health Research Institute; University of Alberta; University of Calgary","funders":"H2020 European Research Council; University of California, San Diego; Samsung; Genentech; Crohn's and Colitis Canada; Shionogi; Celltrion; Celgene; Teva Pharmaceutical Industries; Janssen Pharmaceuticals; Gilead Sciences; Sanofi; National Institute of Diabetes and Digestive and Kidney Diseases; Tillotts Pharma; Amgen; Pfizer; Patient-Centered Outcomes Research Institute; Eli Lilly and Company; Bristol-Myers Squibb; Mylan; GlaxoSmithKline","keywords":"Medicine; Inflammatory bowel disease; Complete remission; Randomized controlled trial; Open label; Internal medicine; Ulcerative colitis; Surgery; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008562681,0.0003057087,0.0006116816,0.0001920474,0.00007679762,0.00005634348,0.0005061669,0.0001056734,0.00001291315],"category_scores_gemma":[0.0007793868,0.0002373943,0.00003858845,0.00006750165,0.00007129626,0.00005929728,0.0002601201,0.00007948934,4.950025e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005552877,"about_ca_system_score_gemma":0.0003199078,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003347301,"about_ca_topic_score_gemma":0.00004555027,"domain_scores_codex":[0.9968824,0.001136876,0.0008760451,0.0005875981,0.0001716269,0.0003455036],"domain_scores_gemma":[0.99856,0.0001466873,0.0004437382,0.000497999,0.0001571603,0.0001943831],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8278123,0.002047508,0.1643194,0.000256797,0.00006372212,0.00001000156,0.00008602063,0.001665513,0.003420677,0.00001978467,0.0001118003,0.0001864393],"study_design_scores_gemma":[0.8236938,0.006374406,0.1658347,0.000654267,0.00003914929,2.803157e-7,0.00003280506,0.002525068,0.0005684821,0.00007118061,0.00005559689,0.0001503252],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.6789162,0.000002845767,0.0006789982,0.00007977486,0.00003401128,0.3202243,0.0000161649,0.000004929925,0.00004279256],"genre_scores_gemma":[0.4916405,0.000001706187,0.008606098,0.0004494865,0.00002154506,0.4989198,0.0001741934,0.0000370039,0.0001495879],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.1872756,"threshold_uncertainty_score":0.968066,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01527880204060522,"score_gpt":0.32751507026901,"score_spread":0.3122362682284048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}